Barclays
IMVT icon

Barclays’s Immunovant IMVT Stock Holding History

Barclays’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-200,000
Closed -$4.95M – 5388
2024
Q4 		$4.95M Hold
200,000
– – ﹤0.01% 2186
2024
Q3 		$5.7M Buy
200,000
+115,900
+138% +$3.42M ﹤0.01% 1977
2024
Q2 		$2.22M Buy
+84,100
New +$2.39M ﹤0.01% 2060
2024
Q1 		– Sell
-15,000
Closed -$632K – 5214
2023
Q4 		$632K Buy
15,000
+600
+4% +$22.1K ﹤0.01% 3734
2023
Q3 		$553K Buy
+14,400
New +$325K ﹤0.01% 2737

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Barclays's IMVT Position: Q1 2026 in Review

Barclays reduced its Immunovant (IMVT) stake by 94% in Q1 2026, selling an estimated $5.63M and leaving 14,900 shares worth $370K. The position accounts for ﹤0.01% of the portfolio, ranked #3357.

Barclays first reported a position in IMVT in Q3 2022 and has held it in 13 quarters since. The position peaked at $7.69M in Q4 2024. 215 funds tracked by Wall St. Rank hold IMVT as of Q1 2026.

  • Barclays held 14,900 shares of Immunovant worth $370K as of Q1 2026.
  • Barclays sold 217,426 Immunovant shares in Q1 2026, an estimated $5.63M.
  • Immunovant made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3357 holding.
  • Barclays first reported a position in Immunovant in Q3 2022 and has held it in 13 quarters since.
  • Barclays's Immunovant position peaked at $7.69M in Q4 2024.
  • 215 funds tracked by Wall St. Rank held Immunovant as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.